MedTrace Logo

A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease

NCT07495813 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 196

Last updated 2026-05-18

No results posted yet for this study

Summary

This study will evaluate safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses (SAD) (Part 1a), multiple ascending doses (MAD) (Part 1b), and the food effect (Part 1c) of RO7763505 in healthy adult participant. In Part 2, the safety, tolerability, PK and PD of multiple doses of RO7763505 in participants with stable coronary artery diseases (CAD).

Conditions

  • Stable Coronary Artery Disease
  • Healthy Volunteers

Interventions

DRUG

RO7763505

Participants will receive RO7763505 as per the schedule described in the protocol.

DRUG

Placebo

Participants will receive matching placebo as per the schedule described in the protocol.

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-03-31
Primary Completion
2028-02-15
Completion
2028-02-15

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07495813 on ClinicalTrials.gov